FDA Adverse Event Malfunction Summary report: N

NV MICROCATHETER

MDR report key: 6517635 · Received April 24, 2017

Report

Report Number
2029214-2017-00532
Event Type
Malfunction
Date Received
April 24, 2017
Date of Event
May 31, 2005
Report Date
March 30, 2017
Manufacturer
COVIDIEN (IRVINE)
Product Code
KRA
PMA / PMN Number
K093750
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
CH
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.

Additional Manufacturer Narrative · 1

CITATION: DONGLEI SONG, BING LENG,YUXIANG GU, WEI ZHU, BIN XU, XIECHENG CHEN, LIANGFU ZHOU. CLINICAL ANALYSIS OF 50 CASES OF BAVM EMBOLIZATION WITH ONYX, A NOVEL LIQUID EMBOLIC AGENT. INTERVENTIONAL NEURORADIOLOGY 11: 179-184, 2005. THE PURPOSE OF THIS ARTICLE WAS TO STUDY THE EMBOLIZATION TECHNIQUE USING ONYX TO TREAT CEREBRAL ARTERIOVENOUS MALFORMATIONS (AVMS), AS WELL AS THE EFFICACY. BETWEEN SEPTEMBER 2003 AND MAY 2005, 50 PATIENTS WITH BAVMS WERE TREATED. THERE WERE 35 MEN AND 15 FEMALE PATIENTS WITH A MEAN AGE OF 28 YEARS. STAGED SESSIONS OF EMBOLIZATION WERE PLANNED FOR PARTIALLY OCCLUDED AVMS. THE AUTHORS CONCLUDE THAT ONYX HAS A UNIQUE AND DISTINCTIVE SUPERIORITY IN TREATING CEREBRAL AVMS. THE REPORTED DEVICE IS EITHER THE MARATHON MICROCATHETER OR ULTRAFLOW MICROCATHETER. THERE IS LIMITED PATIENT AND DEVICE INFORMATION AVAILABLE; IN THIS ARTICLE IT WAS REPORTED THAT BOTH THE MARATHON AND ULTRAFLOW MICROCATHETERS WERE USED. IT WAS NOT REPORTED WHICH MICROCATHETER WAS USED IN THIS PROCEDURE. BOTH THE ULTRAFLOW AND MARATHON INSTRUCTIONS FOR USE (IFU) ADVISE, "SHOULD CATHETER REMOVAL BECOME DIFFICULT, THE FOLLOWING WILL ASSIST IN CATHETER RETRIEVAL. ASSESS THE FOLLOWING PARAMETERS BY OBSERVING THE DISTAL SHAFT OF THE CATHETER: ¿¿ VESSEL STRAIGHTENING ¿¿ TRACTION ON EMBOLIC CAST ¿¿ CATHETER TIP RELEASING FROM EMBOLIC CAST." BASED ON THE REPORTED INFORMATION, REVIEW OF IFUS, AND REVIEW OF LITERATURE TO INVESTIGATE THE COMPLAINT, THE MOST LIKELY CAUSE FOR THE REPORTED EVENT IS PROCEDURE RELATED. ADDITIONAL INFORMATION HAS BEEN REQUESTED, HOWEVER NO RESPONSE HAS BEEN RECEIVED. SHOULD THE INFORMATION BE PROVIDED, A SUPPLEMENTAL REPORT WILL BE SUBMITTED. MDRS FROM THIS EVENT: 2029214-2017-00531, 2029214-2017-00532 MDRS FROM THIS LITERATURE REVIEW: 2029214-2017-00529, 2029214-2017-00530, 2029214-2017-00533.

Description of Event or Problem · 1

MEDTRONIC RECEIVED INFORMATION THROUGH LITERATURE REVIEW A MICROCATHETER (ULTRAFLOW OR MARATHON) WERE LEFT IN 3 PATIENTS AFTER THE EMBOLIZATION PROCEDURE. THE PATIENTS WERE RECEIVING ONYX EMBOLIZATION TO TREAT BRAIN ARTERIO VENOUS MALFORMATIONS (AVMS). AFTER A 6F GUIDING CATHETER WAS INTRODUCED INTO THE INTERNAL CAROTID ARTERY OR VERTEBRAL ARTERY, A FLOW-DIRECTED MICROCATHETER COMPATIBLE WITH DMSO (ULTRAFLOW OR MARATHON) WAS NAVIGATED INTO THE NIDUS OF AVMS WITH THE HELP OF BLOOD FLOW AND/OR A GUIDEWIRE. ANGIOGRAPHY OF THE MICROCATHETER WAS PERFORMED TO CONFIRM A STABLE DISTAL TIP POSITION OF THE MICROCATHETER, CLEAR ANGIOARCHITECTURE OF THE NIDUS, AND VISIBLE DRAINAGE VEIN. ONYX 18 WAS INJECTED AFTER THE MICROCATHETER WAS FLUSHED BY 0.3 ML DMSO. INJECTION AS SLOW AS 0.10-0.15ML PER MINUTE. A GOOD WORKING PROJECTION WAS FOUND TO SEE THE REFLUX CLEARLY AND AN ACCEPTABLE LENGTH OF REFLUX WAS ESTIMATED AND MARKED UNDER FLUOROSCOPY. AFTER MULTIPLE ROUNDS OF INJECTION, REFLUX, AND WAITING, A REFLUX AS LONG AS 1.0 CM TO 1.5 CM COULD BE FORMED AT THE TIP OF THE MICROCATHETER. THE MICROCATHETER WAS ATTEMPTED TO BE IMMEDIATELY REMOVED IF REFLUX EXCEEDED 1.5-2.0 CM. WHEN THE CATHETER WAS WITHDRAWN, THE MICROCATHETER WAS PULLED STRAIGHT FIRST, THEN APPLIED WITH GRADUALLY INCREASED FORCE. HOWEVER, MICROCATHETERS WERE LEFT IN THE BODY OF 3 PATIENTS. THESE 3 PATIENTS WERE TREATED WITH LOW MOLECULE HEPARIN FOR ONE WEEK (FRAXIPARINE, 0.4 ML, I.M., BID). NO ADVERSE REACTION WAS OBSERVED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
299058 NV MICROCATHETER CATHETER, CONTINUOUS FLUSH KRA COVIDIEN (IRVINE) UNK UNK

Patients

Seq Age Sex Outcome Treatment
1 28 YR